QNRX Shariah Compliance
Screening Methodology: AAOIFI
UNLOCK FOR FREE
Last Updated: November 28, 2025
Report Source: 2025 3rd Quarter Report
Quoin Pharmaceuticals Ltd. Stock Analysis QNRX
United States Health Care Nano Cap Report: Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Read More Quoin Pharmaceuticals Ltd (QNRX) Chart
Key Statistics of Quoin Pharmaceuticals Ltd (QNRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$7.41Volume
76.17KP/E Ratio (TTM)
-52 Week Range
Market Cap
4.24MAvg. Volume
18.35KDividend Yield
-Financial Metrics & Statements of Quoin Pharmaceuticals Ltd (QNRX)
FAQ's for Quoin Pharmaceuticals Ltd (QNRX)
- According to Musaffa’s Shariah screening methodology, Quoin Pharmaceuticals Ltd (QNRX) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
Alternate Halal Stocks for Quoin Pharmaceuticals Ltd (QNRX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
